Based on preclinical (animal and cellular) data only, inhibition of NNMT by 5-Amino-1MQ is theorised to: Raise intracellular NAD+ levels Activate SIRT1 and other sirtuins (proteins linked to metabolic regulation) Reduce fat cell (adipocyte) size and proliferation Improve insulin sensitivity These effects have been demonstrated in mouse models (Neelakantan et al., 2019), but robust human clinical trial data are currently absent
A practical note for benchwork: co-formulating two peptides in one vial is a vendor convenience, not a pharmacological assertion
In this guide, we will explore what AOD-9604 is, how it works, and the potential benefits it may offer
This headline number attracts patients who are price-sensitive, but the comparison requires context
Duodenal Switch, which involves both a reduction in stomach size as well as a significant portion of the intestine rerouted to reduce the absorption of calories and nutrients